Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine

(E-pub Ahead of Print)

Author(s): Yangyang Zhang, Minghua Liu*, Jun Wang, Jianlin Huang, Mingyue Guo, Ling Zuo, Biantiao Xu, Shousong Cao, Xiukun Lin.

Journal Name: Current Drug Targets

Become EABM
Become Reviewer


Protein kinases play critical roles in control of cell growth, proliferation, migration, survival and angiogenesis etc. through their catalytic activity. In recent years, numerous protein kinase inhibitors have been developed and are being successfully used clinically. Traditional Chinese medicine (TCM ) represent a large class of bioactive substances, and some of them display anticancer activity via inhibiting protein kinases signal pathway. The phosphoinositide 3-kinase, serine/threonine-specific protein kinases, PI3K/AKT/mTOR), p38mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases (ERK) pathways are involved in most protein kinases-induced cancer cell apoptosis. In the present article, the recent progress of TCMs that exhibited significantly inhibitory activity towards a range of protein kinases are discussed. The prospects and problems in development of the anticancer agents with TCMs are also discussed.

Keywords: DNA damaging agents, BER, NER, DNA polymerase beta, cancer, inhibitor, ERCC1, XPF, XPA, ionizing radiation, chemotherapies target DNA, Traditional Chinese Medicine, protein kinase inhibitors, anticancer activity, PI3K/AKT/mTOR, MAPK, ERK

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389450120666190802125959
Price: $95

Article Metrics

PDF: 1